Skip to content

Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae

Depilatory Cream's Affect on the Occurrence of Pseudofolliculitis Barbae

Status
Withdrawn
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04220502
Enrollment
0
Registered
2020-01-07
Start date
2020-08-01
Completion date
2022-05-03
Last updated
2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudofolliculitis Barbae

Brief summary

Comparing the amount of papules, macules, pustules, and irritation caused by pseudofolluculitis barbae in subjects using depilatory cream versus traditional shaving methods.

Detailed description

Comparing an experimental group that will remove facial hair with magic shave powder gold, and a control group that will continue using traditional shaving methods. Both the subject and a physician will make observations to determine the efficacy of depilatory creams in reducing pseudofolliculits barbae.

Interventions

DRUGMagic Shave Powder Gold

Depilatory Cream for facial hair removal

DEVICETraditional Shaving Methods

Continued facial hair removal using traditional razors

Sponsors

Wayne State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Masking description

Single blinded study where investigator does not know what method of facial hair removal subjects have used

Intervention model description

Comparing an experimental to control group

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male * PFB patient

Exclusion criteria

* Failed sensitivity testing

Design outcomes

Primary

MeasureTime frameDescription
Investigator Global Assessment12 weeksDifference in the investigator assessment of lesions and irritation at baseline and 12 weeks, measured by investigator. The scale title is Investigator Global Assessment, the minimum value is 0, the maximum is 5. Higher scores mean worse outcome.

Secondary

MeasureTime frameDescription
Patient Global Assessment12 weeksDifference in the investigator assessment of disease symptoms at baseline and 12 weeks, measured by patient. The scale title is Patient Global Assessment, the minimum value is 0, the maximum is 5. Higher scores mean worse outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026